BioTuesdays

Category - Markets

Harvest Health & Recreation
Markets

AGP starts Harvest Health at buy; PT $8

Alliance Global Partners launched coverage of Harvest Health & Recreation (CSE:HARV) with a “buy” rating and price target of $8 (Canadian). The stock closed at $3.57 on Feb. 10. “We believe the company is well...

February 11, 2020
Curaleaf Holdings
Markets

AGP starts Curaleaf Holdings at buy; PT $14

Alliance Global Partners initiated coverage of Curaleaf Holdings (CSE:CURA) with a “buy” rating and price target of $14 (Canadian). The stock closed at $8.56 on Feb. 10. “We view Curaleaf as well-positioned to succeed...

February 11, 2020
Abeona Therapeutics
Markets

SVB Leerink starts Abeona Therapeutics at OP; PT $6

SVB Leerink initiated coverage of Abeona Therapeutics (NASDAQ:ABEO) with an “outperform” rating and $6 price target. The stock closed at $2.51 on Feb. 7. “Abeona is a clinical stage gene therapy company with a realistic...

February 10, 2020
Heat Biologics
Markets

Maxim starts Heat Biologics at buy; PT $1

Maxim Group launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and price target of $1. The stock closed at 26 cents on Feb. 5. Heat is developing lead asset, ImPACT, a cell-based immune therapy for...

February 6, 2020
Armata Pharmaceuticals
Markets

Maxim starts Armata Pharma at buy; PT $8

Maxim Group initiated coverage of Armata Pharmaceuticals (NYSE American:ARMP) with a “buy” rating and $8 price target. The stock closed at $3.71 on Feb. 5. Armata is developing phage therapies for the treatment of...

February 6, 2020
Itamar Medical
Markets

Piper Sandler starts Itamar Medical at OW; PT $22

Piper Sandler launched coverage of Itamar Medical (NASDAQ:ITMR) with an “overweight” rating and $22 price target. The stock closed at $16 on Feb. 4. Itamar makes home sleep testing products that are used to diagnose...

February 5, 2020
Avadel
Markets

Ladenburg ups PT for Avadel Pharma to $14 from $8

Ladenburg Thalmann raised its price target for Avadel Pharmaceuticals (NASDAQ:AVDL) to $14 from $8 after the company completed enrollment in its REST-ON Phase 3 study, with a pivotal data readout expected in the second...

February 3, 2020
Harpoon Therapeutics
Markets

HCW starts Harpoon Therapeutics at buy; PT $28

H.C. Wainwright launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and $28 price target. The stock closed at $13.29 on Jan. 31. Harpoon is advancing a proprietary platform of redirected T cell...

February 3, 2020

Subscribe

Sign up to our weekly BioTuesdays newsletter.